Cargando…

User preference for a portable syringe pump for iloprost infusion

PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Laria, Antonella, Lurati, Alfredo Maria, Re, Katia Angela, Marrazza, Maria Grazia, Mazzocchi, Daniela, Farina, Alberto, Scarpellini, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447001/
https://www.ncbi.nlm.nih.gov/pubmed/26056502
http://dx.doi.org/10.2147/PROM.S81473
_version_ 1782373532733276160
author Laria, Antonella
Lurati, Alfredo Maria
Re, Katia Angela
Marrazza, Maria Grazia
Mazzocchi, Daniela
Farina, Alberto
Scarpellini, Magda
author_facet Laria, Antonella
Lurati, Alfredo Maria
Re, Katia Angela
Marrazza, Maria Grazia
Mazzocchi, Daniela
Farina, Alberto
Scarpellini, Magda
author_sort Laria, Antonella
collection PubMed
description PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy. PATIENTS AND METHODS: Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde(®) pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde(®). RESULTS: Patients’ answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8–10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug. CONCLUSION: Iloprost administration with Infonde(®) pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde(®) on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion.
format Online
Article
Text
id pubmed-4447001
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44470012015-06-08 User preference for a portable syringe pump for iloprost infusion Laria, Antonella Lurati, Alfredo Maria Re, Katia Angela Marrazza, Maria Grazia Mazzocchi, Daniela Farina, Alberto Scarpellini, Magda Patient Relat Outcome Meas Original Research PURPOSE: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy. PATIENTS AND METHODS: Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde(®) pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde(®). RESULTS: Patients’ answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8–10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug. CONCLUSION: Iloprost administration with Infonde(®) pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde(®) on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion. Dove Medical Press 2015-05-19 /pmc/articles/PMC4447001/ /pubmed/26056502 http://dx.doi.org/10.2147/PROM.S81473 Text en © 2015 Laria et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Laria, Antonella
Lurati, Alfredo Maria
Re, Katia Angela
Marrazza, Maria Grazia
Mazzocchi, Daniela
Farina, Alberto
Scarpellini, Magda
User preference for a portable syringe pump for iloprost infusion
title User preference for a portable syringe pump for iloprost infusion
title_full User preference for a portable syringe pump for iloprost infusion
title_fullStr User preference for a portable syringe pump for iloprost infusion
title_full_unstemmed User preference for a portable syringe pump for iloprost infusion
title_short User preference for a portable syringe pump for iloprost infusion
title_sort user preference for a portable syringe pump for iloprost infusion
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447001/
https://www.ncbi.nlm.nih.gov/pubmed/26056502
http://dx.doi.org/10.2147/PROM.S81473
work_keys_str_mv AT lariaantonella userpreferenceforaportablesyringepumpforiloprostinfusion
AT luratialfredomaria userpreferenceforaportablesyringepumpforiloprostinfusion
AT rekatiaangela userpreferenceforaportablesyringepumpforiloprostinfusion
AT marrazzamariagrazia userpreferenceforaportablesyringepumpforiloprostinfusion
AT mazzocchidaniela userpreferenceforaportablesyringepumpforiloprostinfusion
AT farinaalberto userpreferenceforaportablesyringepumpforiloprostinfusion
AT scarpellinimagda userpreferenceforaportablesyringepumpforiloprostinfusion